Meeting
2015 Gastrointestinal Cancers Symposium
Comparative circulating tumor DNA levels for KRAS mutations in patients with nonresectable pancreatic cancer.
Authors
Julia S. Johansen
Department of Oncology, Herlev Hospital, Herlev, Denmark
Julia S. Johansen , Cecile Rose T. Vibat , Dan Calatayud , Benny Vittrup Jensen , Jane Preuss Hasselby , Eric Andrew Collisson , Timothy Lu , Jason C. Poole , Mark Erlander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 288)
DOI
10.1200/jco.2015.33.3_suppl.288
Abstract #
288
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients.
First Author: Julia S. Johansen
Poster
2020 ASCO Virtual Scientific Program
Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies.
First Author: Andrew Eugene Hendifar
Poster
2018 Gastrointestinal Cancers Symposium
Clinical significance of monitoring KRAS in tissue and serum of pancreatic cancer patients.
First Author: Fumiaki Watanabe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Carter Norton